When referring a patient suspected of having glioblastoma multiforme, offer a standard structural MRI (T2 weighted, FLAIR, DWI series, and T1 pre- and post-contrast volume) as the initial diagnostic test, unless contraindicated NICE NG99.
Refer the patient to a specialist multidisciplinary team at the first radiological diagnosis for management of their tumour NICE NG99.
Include all relevant clinical information, such as the patient's symptoms, neurological findings, and any previous investigations or treatments.
Report all glioma specimens according to the latest WHO classification, including molecular markers such as IDH1/2 mutations, ATRX mutations, 1p/19q codeletion, histone H3 K27M mutations, BRAF fusion/mutation, and MGMT promoter methylation status NICE NG99.
Ensure the referral includes details of the imaging findings, suspected tumour location, and any planned or previous surgical interventions.